DME Resource Center

Editorially independent content supported with advertising.

Videos

Difficult-To-Manage DME in a Patient Who Travels Frequently

Inconsistent Follow Up May Affect Final Vision

Treatment of DME With Dexamethasone Implant and
Bevacizumab Injection is Compared in Three Patient Cases

Saving Vision and Reducing Burden: Balancing Care with Cost

Diabetic Eye Disease Treated in Two Patient Cases

DME Management in a Patient with Elevated IOP

Tackling Challenging DME Cases

Anti-VEGF Injections vs. Steroid Implant in
Patients With Persistent DME

Resources

Beyond the Clinical Trials

An educational series on the implications of managing the ocular manifestations of diabetes in real world settings. In Part 1 the series, Raj K. Mutari, MD, of the Midwest Eye Institute in Indianapolis, Indiana, addresses the changing disease trends of diabetes around the world.

Read more...
Beyond the Clinical Trials - Part II

An educational series on the implications of managing the ocular manifestations of diabetes in real world settings. In Part 2 of the series, Gary Scheiner, MS, CDE, a certified diabetes educator, talks about the comanagement of patients and the difficulties all members of a patient’s health care team have in educating about diabetes and motivating patients to be adherent to their care regimen.

Read more...
Beyond the Clinical Trials - Part III

An educational series on the implications of managing the ocular manifestations of diabetes in real world settings. In Part 3 of this ongoing series, Victor H. Gonzalez, MD, of Valley Research Institute in McAllen, Texas, explores the technology necessary to establish a baseline for each patient, how the clinical examination guides the use of imaging, and how to use optical coherence tomography and fluorescein angiography to follow patients over time. An overlooked aspect in the use of imaging, according to Dr. Gonzalez, is the changing reimbursement landscape for retina specialists and how it may change how patients are managed in the very near future.

Read more...
Beyond the Clinical Trials - Part IV

An educational series on the implications of managing the ocular manifestations of diabetes in real world settings. In Part 4 of this ongoing series, two retina specialists present clinical cases that reflect the sometimes challenging aspects of dealing with patients in the clinic on a day-to-day basis. First, Sunir J. Garg, MD, an associate professor of ophthalmology with the Retina Service of Wills Eye Hospital and Thomas Jefferson University, presents a case of a patient who was nonadherent to medical advice—and as a consequence, she may have left vision on the table. Then, Rishi P. Singh, MD, a staff physician at Cole Eye Institute, Cleveland Clinic, medical director of the clinical systems office in Cleveland Clinic, and an assistant professor of ophthalmology at Case Western Reserve University, offers a case of a patient with history of glaucoma but who previously was responsive to intravitreal steroid injections but not to anti-VEGF therapy. Would additional steroid therapy in this patient wind up causing unwanted adverse outcomes?

Read more...

Beyond the Clinical Trials - Part V

An educational series on the implications of managing the ocular manifestations of diabetes in real world settings. In Part 5, Sanket U. Shah, MD, a third-year resident at Indiana University School of Medicine in Indianapolis, Ind., and Raj K. Maturi, MD, of the Midwest Eye Institute in Indianapolis, Ind., share a comparison of the results of two differenttreatments for DME in several patient cases.

Read more...
Beyond the Clinical Trials - Part VI

An educational series on the implications of managing the ocular manifestations of diabetes in real world settings. In Part 6 of the series, Anat Loewenstein, MD, of the Tel Aviv Sourasky Medical Center and Tel Aviv University in Israel, shares several cases in which she treated patients with DME using a corticosteroid implant

Read more...
Beyond the Clinical Trials - Part VII

An educational series on the implications of managing the ocular manifestations of diabetes in real world settings. In Part 7 of the series, Daniel Kiernan, MD, of Ophthalmic Consultants of Long Island in Long Island, N.Y., details his use of anti-VEGF therapy and sustained-release corticosteroids in the treatment of patients with DME. In the patient cases he shares, he also includes a short recap on the cost to maintain each patient’s vision with the chosen treatment.

Read more...
Beyond the Clinical Trials - Part VIII

An educational series on the implications of managing the ocular manifestations of diabetes in real world settings. In Part 8 of the series, Michael A. Singer, MD, of Medical Center Ophthalmology Associates in Texas, shares his treatment strategies in two patients with diabetic eye disease.

Read more...

Beyond the Clinical Trials - Part IX

An educational series on the implications of managing the ocular manifestations of diabetes in real world settings. In Part 9 of the series, John D. Pitcher III, MD, of Eye Associates of New Mexico, gives readers a look at his approaches to treating three patients with diabetic eye disease.

Read more...
Beyond the Clinical Trials - Part X

An educational series on the implications of managing the ocular manifestations of diabetes in real world settings. In Part 10 of the DME Resource Center print series, Andre Witkin, MD, an assistant professor at Tufts Medical Center, shares two cases in which he had to change his strategy for treating patients with DME.

Read more...
Beyond the Clinical Trials - Part XI

An educational series on the implications of managing the ocular manifestations of diabetes in real world settings. In Part 11 of this series, Maria H. Berrocal, MD, an assistant professor in the department of ophthalmology at the University of Puerto Rico, details her management of three patients with DME.

Read more...
Beyond the Clinical Trials - Part XII

An educational series on the implications of managing the ocular manifestations of diabetes in real world settings. In this installment of the DME Resource Center, Part 12, Jeremy D. Wolfe, MD, describes his experience in a small, shortterm clinical trial directly comparing anti-VEGF and corticosteroid therapies in the two eyes of a series of patients with DME. He explores the possible reasons for the differences in outcomes observed in the trial.

Read more...

Beyond the Clinical Trials - Part XII

An educational series on the implications of managing the ocular manifestations of diabetes in real world settings. In this installment of the DME Resource Center, Part 12, Jeremy D. Wolfe, MD, describes his experience in a small, shortterm clinical trial directly comparing anti-VEGF and corticosteroid therapies in the two eyes of a series of patients with DME. He explores the possible reasons for the differences in outcomes observed in the trial.

Articles

Retina News

NONVIRAL GENE THERAPY FOR UVEITIS BEGINS CLINICAL TRIAL A nonviral gene thera… Read Article

Is Automated Interpretation of DR Images in Our Future?

Peter A. Karth, MD, MBA, and Ehsan Rahimy, MD

Recently, the terms artificial intelligence (AI) and machine learning have b… Read Article

Exploring Two Photocoagulation Modes for DME

Caesar K. Luo, MD, and Melissa D. Neuwelt, MD

Continuous wave (CW) laser photocoagulation has been a mainstay in the treat… Read Article

Retina News

LONGER-TERM DME OUTCOMES PREDICTED BY EARLY RESPONSE TO ANTI-VEGF THERAPY Eye… Read Article

Lasers in Current Retina Practice

Mahima Jhingan, MD; Komal Agarwal, MD; and Jay Chhablani, MD

img class="left" src="http://retinatoday.com/images/articles/2017-01/Chhablani_j… Read Article

Tie Fighters

Aron Shapiro; David Hollander, MD; and Lisa Smith

img class="left" src="http://retinatoday.com/images/articles/2017-01/Smith_Lisa_… Read Article

Pharmacologic Treatment of PDR and DME

Stephen G. Schwartz, MD, MBA, and Ingrid U. Scott, MD, MPH

The Diabetic Retinopathy Clinical Research Network (DRCR.net), formed in 200… Read Article

Recapping the Past 12 Months

the staff of Retina Today

We are at the tail end of another successful year for the retina world. It is pr… Read Article

Using EHR Tools to Optimize Ophthalmologic Outcomes in Patie…

Rishi P. Singh, MD, and Ingrid U. Scott, MD, MPH

Although ophthalmologists provide specialized services for patients with dia… Read Article

News

CMS Releases Proposed 2017 ASC Payment Rates for Ophthalmic Services The … Read Article

The Role of Laser in the Pharmacologic Era of Retina

Baruch Kuppermann, MD, PhD

Although the retina subspecialty has largely embraced pharmacology in the tr… Read Article

Vitrectomy With ILM Removal for DME Resistant to Conventiona…

Sergio Rojas, MD, and Ezequiel Diaz Benitez, MD

Diabetic macular edema (DME) is an important cause of visual loss in patient… Read Article

A Postmodern View of Anti-VEGF Treatment

Nancy M. Holekamp, MD

At one time, laser photocoagulation was the only option for treating patient… Read Article

Will a New Low-Cost Option Join the Anti-VEGF Fold?

Brian C. Joondeph, MD, MPS

As physicians, we all know the importance of being reimbursed and paid for s… Read Article

News

Study: Higher Risk for Neurodevelopmental Disabilities With Bevacizumab for ROP … Read Article

Why “Not 20/20” After an Excellent Phacoemulsification S…

Jay Chhablani, MD, and Vivek Gupta, MBBS

Advanced surgical techniques have improved the outcomes of cataract surgery … Read Article

Ocular Drug Delivery Systems

Randall V. Wong, MD

Prior to the adoption of intravitreal injections for the treatment of retina… Read Article

News

RETROSPECTIVE STUDY: L-DOPA WAS PROTECTIVE AGAINST WET AMD Exogenous L-DOPA… Read Article

American Academy of Ophthalmology 2015 Annual Meeting

The American Academy of Ophthalmology (AAO) 2015 Annual Meeting was held Novem… Read Article

Drug Delivery to the Posterior Segment

Daniel D. Esmaili, MD; and David S. Boyer, MD

At a Glance • Intravitreal injection is the current drug delivery meth… Read Article

Treatment of DME With the 0.19-mg Fluocinolone Acetonide Imp…

Scott W. Cousins, MD

As part of this review of sustained-release steroid implants, I will discuss the… Read Article

Dexamethasone Intravitreal Implant: Pharmacology and Clinica…

Yoshihiro Yonekawa, MD; and Jeremy D. Wolfe, MD

The dexamethasone intravitreal implant (Ozurdex, Allergan) is approved by the US… Read Article

Laser Use and the Future of Retina Practice

Anat Loewenstein, MD

At a Glance • Although pharmacologic therapy provides excellent result… Read Article

A New Self-Testing System for Patients With AMD or DME

Raj K. Maturi, MD

At a Glance • Home monitoring of some retinal diseases is desirable be… Read Article

Individualizing Therapy for DME

Antonio Capone Jr, MD

At a Glance • The degree to which VEGF or inflammation is the more imp… Read Article

Examining the Systemic Safety of Anti-VEGF Agents

Karen Roman, Editor-in-Chief

At a Glance • Anti-VEGF agents can enter the circulation and reduce sy… Read Article

A Dual-Mechanism Drug for Vitreoretinal Diseases

Baruch D. Kuppermann, MD, PhD

At a Glance • Integrins are cell surface receptors involved in angioge… Read Article

Incorporating New Technologies Into Practice: The Big Pictur…

Szilárd Kiss, MD

At a Glance • It is important to weigh the visual benefits and potenti… Read Article

Additional Perspectives on Protocol T

Bryan Bechtel, Editor-in-Chief

The results of the DRCR.net Protocol T study have been released to the re… Read Article

What Is New with Anti-VEGF Therapy for DME

Dilsher S. Dhoot, MD, and Dante Pieramici, MD

The landscape for the treatment of diabetic macular edema (DME) is evolving. O… Read Article

The Role of Corticosteroid Implants in DME

Nancy Holekamp, MD

Anti-VEGF drugs are appropriately considered first line therapy for patient… Read Article

What is the Current Role of Laser Therapy in the Management …

Sam E. Mansour, MSc, MD, FRCS(C), FACS

Diabetic macular edema (DME) is a leading cause of vision loss among indivi… Read Article

Crowdsourcing for Rapid Fundus Photograph Interpretation

Christopher J. Brady, MD

Screening for diabetic retinopathy (DR) with retinal fundus examination is … Read Article

Switching Therapy in Patients with DME

David Eichenbaum, MD; John W. Kitchens, MD; and Andrew A. Moshfeghi, MD, MBA

There Are Several Ways to Define Treatment Failure By David Eichenbaum,… Read Article

Ultra-Widefield Imaging: Advancing the Understanding and Man…

Paul E. Tornambe, MD, FACS

The rising incidence of diabetes in the US population and the cresting wave of… Read Article

Retina News

Joint Technical Report Highlights Viability of Telemedicine for ROP Evaluation… Read Article

Exploring the DME Treatment Decision Tree

An Interview with David Eichenbaum, MD

There is now a variety of options for treating patients with diabetic macul… Read Article

Frequently Asked Questions About the Dexamethasone Implant

Jay Chhablani, MD; Paolo Lanzetta, MD; Adrian Koh, MBBS, MMed (Ophth), FRCS (Ed), FAMS; and Michael …

How fast does the DEX implant reduce macular edema, and in which disease states … Read Article

Investigating Treatment Options for Diabetic Macular Edema

Aron Shapiro with Michael Tolentino, MD, and Edward Quinlan, MD

What are some qualifying features that identify patients who will work well in a… Read Article

Status of Sustained-release Steroids for Diabetic Macular Ed…

With David S. Boyer, MD

Retina Today: Where do corticosteroid sustained-release devices fit in the treat… Read Article

Using Aflibercept to Treat Diabetic Macular Edema

Diana V. Do, MD

Untreated diabetic macular edema (DME) can lead to vision loss in patients with … Read Article

Developments in the Treatment of Diabetic Macular Edema

With Quan Dong Nguyen, MD, MSc

Treatments for diabetic macular edema (DME) continue to be developed. Retina Tod… Read Article

A Minimalist Approach to Surgery for Diabetic Retinal Detach…

María H. Berrocal, MD

Vitrectomy has evolved in the past 45 years, from very large incisions with Kasn… Read Article

Multispot and Multiwavelength Lasers for Diabetic Retinopath…

Manish Nagpal, MS, DO, FRCS; Chaitanya Shukla, DNB; and Kartikey Kothari, MS

Since the ETDRS, panretinal photocoagulation (PRP) or macular laser in the form … Read Article

Management of Diabetic Macular Edema in the UK National Heal…

Sahar Al-Husainy, MBChB, FRCS(Ed), MRCOphth; and Jonathan M. Gibson, MB, BS, MD, FRCS(Ed), FRCOphth

In recent years, diabetes mellitus has become a global health problem. In the Un… Read Article

Optimizing Treatment for Diabetic Macular Edema With Laser

Rahul N. Khurana, MD

Although anti-VEGF monotherapy is effective for treating diabetic macular edema … Read Article

Controversies in Vitreoretinal Surgery: Is Vitrectomy an App…

Tarek S. Hassan, MD and Julia A. Haller, MD

These articles are based on the debate-style presentations at the American Acade… Read Article

Multispot Laser Photocoagulation

Sebastien Guigou, MD

Laser photocoagulation is a proven treatment for retinal pathologies and has bee… Read Article

Fluorescein Angiography and Optical Coherence Tomography Cor…

Jay Chhablani, MD; and Aditya Sudhalkar, MD

Fluorescein angiography (FA) and optical coherence tomography (OCT) scans are im… Read Article

News

New Data Reveal Real-World Benefits of Iluvien Treatment

Latest data from an ongoing audit of real-life UK clinical practice published online today in Eye show the number of chronic diabetic macular edema (DME) patients with 6/12 vi…

Spark Therapeutics Receives Rare Pediatric Disease Designation for Investigational Luxturna (Voretigene Neparvovec) from FDA

Spark Therapeutics announced that the Offices of Orphan Products Development and Pediatric Therapeutics of the FDA have designated investigational Luxturna (voretige…

pSivida Out-Licenses EMEA Rights for Durasert Treatment for Posterior Segment Uveitis While Retaining US Commercial Rights

pSivida announced an amendment of its exclusive license and collaboration agreement with Alimera Sciences that grants Alimera rights to pSivida’s Durasert 3-year treatme…

Nightstar Raises $45 Million to Fund Development of Gene Therapies for Blinding Retinal Diseases

NightstaRx announced the completion of a $45 million Series C financing transaction, the proceeds of which will be used for the upcoming phase 3 trial for Nightstar’s le…

Risk of Age-related Macular Degeneration Higher With Myeloproliferative Neoplasms

Patients with chronic myeloproliferative neoplasms (MPNs) have an increased risk of age-related macular degeneration (AMD), according to a Danish registry study. "Blood c…

DME Resource Center

Videos

Difficult-To-Manage DME in a Patient Who Travels Frequently

DME Clinical Case Review #1

DME Clinical Case Review #2

DME Clinical Case Review #3

Inconsistent Follow Up May Affect Final Vision

Treatment of DME With Dexamethasone Implant andBevacizumab Injection is Compared in Three Patient Cases

Ozurdex for DME

Saving Vision and Reducing Burden: Balancing Care with Cost

Diabetic Eye Disease Treated in Two Patient Cases

DME Management in a Patient with Elevated IOP

Tackling Challenging DME Cases

Managing Difficult DME Cases

Anti-VEGF Injections vs. Steroid Implant inPatients With Persistent DME

Now Showing

Now Showing

Now Showing

Now Showing

Now Showing

Now Showing

Now Showing

Now Showing

Now Showing

Now Showing

Now Showing

Now Showing

Now Showing

Resources

Articles

Peter A. Karth, MD, MBA, and Ehsan Rahimy, MD

Caesar K. Luo, MD, and Melissa D. Neuwelt, MD

Mahima Jhingan, MD; Komal Agarwal, MD; and Jay Chhablani, MD

Aron Shapiro; David Hollander, MD; and Lisa Smith

Stephen G. Schwartz, MD, MBA, and Ingrid U. Scott, MD, MPH

the staff of Retina Today

Rishi P. Singh, MD, and Ingrid U. Scott, MD, MPH

Baruch Kuppermann, MD, PhD

Sergio Rojas, MD, and Ezequiel Diaz Benitez, MD

Nancy M. Holekamp, MD

Brian C. Joondeph, MD, MPS

Jay Chhablani, MD, and Vivek Gupta, MBBS

Randall V. Wong, MD

Daniel D. Esmaili, MD; and David S. Boyer, MD

Scott W. Cousins, MD

Yoshihiro Yonekawa, MD; and Jeremy D. Wolfe, MD

Anat Loewenstein, MD

Raj K. Maturi, MD

Antonio Capone Jr, MD

Karen Roman, Editor-in-Chief

Baruch D. Kuppermann, MD, PhD

Szilárd Kiss, MD

Bryan Bechtel, Editor-in-Chief

Dilsher S. Dhoot, MD, and Dante Pieramici, MD

Nancy Holekamp, MD

Sam E. Mansour, MSc, MD, FRCS(C), FACS

Christopher J. Brady, MD

David Eichenbaum, MD; John W. Kitchens, MD; and Andrew A. Moshfeghi, MD, MBA

Paul E. Tornambe, MD, FACS

An Interview with David Eichenbaum, MD

Jay Chhablani, MD; Paolo Lanzetta, MD; Adrian Koh, MBBS, MMed (Ophth), FRCS (Ed), FAMS; and Michael …

Aron Shapiro with Michael Tolentino, MD, and Edward Quinlan, MD

With David S. Boyer, MD

Diana V. Do, MD

With Quan Dong Nguyen, MD, MSc

María H. Berrocal, MD

Manish Nagpal, MS, DO, FRCS; Chaitanya Shukla, DNB; and Kartikey Kothari, MS

Sahar Al-Husainy, MBChB, FRCS(Ed), MRCOphth; and Jonathan M. Gibson, MB, BS, MD, FRCS(Ed), FRCOphth

Rahul N. Khurana, MD

Tarek S. Hassan, MD and Julia A. Haller, MD

Sebastien Guigou, MD

Jay Chhablani, MD; and Aditya Sudhalkar, MD

Videos In This Series

2 Cases of Refractory DME

Diabetic Eye Disease Treated in Two Patient Cases

Saving Vision and Reducing Burden: Balancing Care with Cost

Treatment of DME with Steroids

Dexamethasone Implant vs. Bevacizumab for the Treatment of DME

Treatment Options for Patients with DME, Part 1

Treatment Options for Patients with DME, Part 2

Treatment of DME With Dexamethasone Implant and
Bevacizumab Injection is Compared in Three Patient Cases

Anti-VEGF Injections vs. Steroid Implant in
Patients With Persistent DME